Solid Tumor, Breast Cancer, Biliary Tract Cancer, Soft Tissue Sarcoma, Colon Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
The duration of your participation depends on how well your disease responds to the study treatment.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
- Participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced or metastatic
- Participant must have discontinued all previous therapies for cancer
- Participant must not have current acute leukemia
- Participant must not have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease